<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7484576\results\search\testTrace\results.xml">
  <result pre="to identify epidemiological and pathogenic mechanisms of COVID-19 to find" exact="treatment" post="regimens and effective therapeutic modalities for future prevention. Herein,"/>
  <result pre="host resistance against viral invade and infectivity. IFN-Î± inhibits virus" exact="infection" post="by direct interference with the replication cycle and boosting"/>
  <result pre="might be advocated as a candidate medication for the therapeutic" exact="treatment" post="of SARS-CoV-2. Lopinavir-ritonavir was recognized as a first protease-inhibiting"/>
  <result pre="of key proteins of the SARS-CoV-2. Evidence suggests that lopinavir-ritonavir" exact="treatment" post="either in individual or amalgamation with other anti-viral therapies"/>
  <result pre="suppress SARS-CoV and MERS-CoV in vivo.27,28 It strappingly prevented SARS-CoV-2" exact="infection" post="in a recent in vitro investigation at low-micro molar"/>
  <result pre="of remdesivir.29 Though remdesivir exhibits many merits for curing SARS-CoV-2" exact="infection" post="and pneumonia, randomized controlled trials (RCTs) are still necessitated"/>
  <result pre="cinanserin can be a suitable therapeutic option for suppressing the" exact="infection" post="caused by SARS-CoV-2. Flavonoids are an imperative group of"/>
  <result pre="have been widely accepted and acquired remarkable achievements in the" exact="treatment" post="of numerous chronic and lethal viral diseases.39 From the"/>
  <result pre="inoculation. On February 26, 2020, Novavax has announced starting animal" exact="testing" post="on COVID-19 vaccine candidates because of their earlier experiences"/>
  <result pre="up immunological responses, predominantly antigen-specific CD8+ T-cell-assisted responses against SARS-CoV" exact="infection" post="are documented in patent application WO2005081716.65 Immune responses, particularly"/>
  <result pre="the virus. Comprehensive knowledge of the SARS-CoV-2 pathogenesis, including the" exact="infection" post="of target organs and the route and mechanism of"/>
  <result pre="reduction in nasal shedding. On the other hand, if the" exact="infection" post="occurs in the lungs or other organs through viremia,"/>
  <result pre="to prevent viremia. Furthermore, people who have recovered from COVID-19" exact="infection" post="but are again primed to the virus-like seasonal influenza,"/>
  <result pre="and deployment of passive immunization approaches for prophylactic and therapeutic" exact="treatment" post="of patients. Convalescent plasma treatment using plasma-containing antibodies from"/>
  <result pre="approaches for prophylactic and therapeutic treatment of patients. Convalescent plasma" exact="treatment" post="using plasma-containing antibodies from recovered patients would be the"/>
  <result pre="of the anti-viral effects of interferon-Î± against a SARS-like coronoavirus" exact="infection" post="in vitro. Cell Res. 2006;16(2):220â€&quot;29. doi:10.1038/sj.cr.7310030.16474437 13.HaagmansBL, KuikenT, MartinaBE,"/>
  <result pre="AmerongenG, TashiroMPegylated interferon-Î± protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med. 2004;10(3):290â€&quot;93. doi:10.1038/nm1001.14981511 14.LoutfyMR, BlattLM, SiminovitchKA,"/>
  <result pre="KingM, ArribasJ, BeallG, RuaneP, BrunSLopinavirâ€&quot;ritonavir versus nelfinavir for the initial" exact="treatment" post="of HIV infection. New Engl J Med. 2002;346(26):2039â€&quot;46. doi:10.1056/NEJMoa012354.12087139"/>
  <result pre="ChengVCC, HungIFN, WongMML, ChanKH, ChanKS, PeirisJSMRole of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252â€&quot;56."/>
  <result pre="25.ZhangN, WangL, DengX, LiangR, SuM, HeC, DuLRecent advances in the" exact="detection" post="of respiratory virus infection in humans. J Med Virol."/>
  <result pre="SuM, HeC, DuLRecent advances in the detection of respiratory virus" exact="infection" post="in humans. J Med Virol. 2020;92(4):408â€&quot;17. doi:10.1002/jmv.25674.31944312 26.XuXW, WuXX,"/>
  <result pre="FeldmannF, CroninJ, JordanR, OkumuraA, ThomasT, FeldmannHProphylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection. Proc"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res. 2013;23(2):300â€&quot;02. doi:10.1038/cr.2012.165.23208422 42.VincentMJ,"/>
  <result pre="RollinPE, KsiazekTG, NicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2(1):69. doi:10.1186/1743-422X-2-69.16115318 43.WangM, CaoR, ZhangL,"/>
 </snippets>
</snippetsTree>
